Lupin launches HIV tablets in the US
IANS Mar 30, 2017
Pharma major Lupin Ltd on Tuesday announced the launch of generic Abacavir and Lamivudine tablets for HIV in the US.
In a regulatory filing in BSE, the company said it has launched Abacavir and Lamivudine tablets 600 mg/300 mg after an approval from the United States Food and Drug Administration (USFDA) earlier. According to Lupin, Abacavir and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company's Epzicom tablets, 600 mg/300 mg. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Epzicom tablets had US sales of $388.1 million, the company said.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries